Trials (Candiolo Cancer Institute): Revision history

15 December 2025

• curprev 12:2812:28, 15 December 2025‎ Francine talk contribs‎ 102,878 bytes +171‎ No edit summary undo

6 December 2025

• curprev 12:4012:40, 6 December 2025‎ Lucas talk contribs‎ m 102,707 bytes +1,701‎ Update categories. undo

4 December 2025

• curprev 01:0701:07, 4 December 2025‎ Larysse talk contribs‎ 101,006 bytes +47‎ No edit summary undo

2 December 2025

• curprev 13:5813:58, 2 December 2025‎ Lucas talk contribs‎ m 100,959 bytes +90‎ Update categories. undo

4 December 2023

• curprev 17:1517:15, 4 December 2023‎ Francine talk contribs‎ 100,869 bytes +100,869‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Candiolo Cancer Institute page '''NCTID''': NCT04296890 '''Title''': A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression '''Study Summary''': This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-res..."